Trial Profile
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 21 Jun 2021 Planned End Date changed from 20 Apr 2021 to 22 Feb 2025.
- 15 Dec 2020 Planned End Date changed from 1 Nov 2020 to 20 Apr 2021.
- 15 Dec 2020 Planned primary completion date changed from 1 Nov 2020 to 20 Apr 2021.